Tag: femoropopliteal disease

One-year results show ‘superior’ primary patency rate for Eluvia DES compared...

One-year results presented at Vascular Interventional Advances (VIVA) 2021 in Las Vegas (Oct. 5–7) from the EMINENT trial demonstrated the superiority of the Eluvia...

Two-year Ranger DCB data demonstrate ‘sustained, high rate’ of device efficacy

Patients treated with Boston Scientific’s Ranger drug-coated balloon (DCB) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year results...

VIVA 2021: IN.PACT Admiral DCB found to provide ‘high five-year freedom...

Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically driven target lesion revascularization (TLR) among prespecified chronic total occlusion...

Latest meta-analysis on paclitaxel in peripheral arterial disease provokes mixed reception

“There appears to be heightened risk of major amputation after use of paclitaxel-coated balloons in the peripheral arteries,” findings from a systematic review...

Veterans study: No evidence of increased risk of death with use...

A study of more than 10,000 U.S. veterans with peripheral arterial disease (PAD) undergoing endovascular interventions in the femoropopliteal segment found that rates of...

How to succeed in vascular surgery: A guide for the aspiring...

Disclaimer: The views expressed here do not reflect those of Mayo Clinic, the Society for Vascular Surgery, Vascular Specialist, or even the author, for...

LINC 2021: Long-term data show sustained efficacy and safety of paclitaxel...

A key theme among the late-breaking trial data presented at the recent LINC 2021 (the Leipzig Interventional Course), held digitally from Jan. 25–29, was the...